Related Experiment Video
Updated: Jun 1, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a
Daniel J Crespin1, Jerome J Federspiel, Andrea K Biddle
1Department of Health Policy and Management, University of North Carolina, Chapel Hill, NC, USA.
Insights
Universal ticagrelor prescription improves quality-adjusted life years for acute coronary syndrome patients. This strategy is cost-effective, offering significant benefits below typical spending thresholds for healthcare interventions.
Area of Science:
- Cardiovascular Medicine
- Pharmacoeconomics
- Genetics
Background:
- Clopidogrel effectiveness is reduced in patients with genetic mutations affecting its metabolism.
- Ticagrelor offers greater clinical efficacy and is not dependent on genetic activation.
- Patent expiration of clopidogrel may lead to significant price differences compared to ticagrelor.
Purpose of the Study:
- To evaluate the cost-effectiveness of universal ticagrelor use versus genotype-guided antiplatelet therapy.
- To compare the economic and clinical outcomes of different antiplatelet strategies in acute coronary syndrome (ACS) patients.
Main Methods:
- A hybrid decision tree/Markov model was employed to simulate 5-year costs and outcomes.
- Medicare-enrolled ACS patients were analyzed for genotype-driven versus ticagrelor-only treatment arms.
- Quality-adjusted life years (QALYs) and life years gained were key outcome measures, using data from the Platelet Inhibition and Patient Outcomes trial.
Main Results:
- Universal ticagrelor demonstrated an incremental cost-effectiveness ratio (ICER) of $10,059 per QALY compared to genotype-driven treatment.
- The ICER was sensitive to ticagrelor pricing and its hazard ratio for death relative to clopidogrel.
- Probabilistic analyses indicated universal ticagrelor remained cost-effective (below $50,000/QALY) in 97.7% of simulations.
Conclusions:
- Universal prescription of ticagrelor is a cost-effective strategy for ACS patients.
- This approach significantly increases quality-adjusted life years.
- The cost per QALY gained remains below commonly accepted thresholds for healthcare interventions.
Background:
Clopidogrel's effectiveness is likely reduced significantly for prevention of thrombotic events after acute coronary syndrome (ACS) in patients exhibiting a decreased ability to metabolize clopidogrel into its active form. A genetic mutation responsible for this reduced effectiveness is detectable by genotyping. Ticagrelor is not dependent on gene-based metabolic activation and demonstrated greater clinical efficacy than clopidogrel in a recent secondary prevention trial. In 2011, clopidogrel will lose its patent protection and likely will be substantially less expensive than ticagrelor.
Objective:
To determine the cost-effectiveness of ticagrelor compared with a genotype-driven selection of antiplatelet agents.
Methods:
A hybrid decision tree/Markov model was used to estimate the 5-year medical costs (in 2009 US$) and outcomes for a cohort of ACS patients enrolled in Medicare receiving either genotype-driven or ticagrelor-only treatment. Outcomes included life years and quality-adjusted life years (QALYs) gained. Data comparing the clinical performance of ticagrelor and clopidogrel were derived from the Platelet Inhibition and Patient Outcomes trial.
Results:
The incremental cost-effectiveness ratio (ICER) for universal ticagrelor was $10,059 per QALY compared to genotype-driven treatment, and was most sensitive to the price of ticagrelor and the hazard ratio for death for ticagrelor compared with clopidogrel. The ICER remained below $50,000 per QALY until a monthly ticagrelor price of $693 or a 0.93 hazard ratio for death for ticagrelor relative to clopidogrel. In probabilistic analyses, universal ticagrelor was below $50,000 per QALY in 97.7% of simulations.
Conclusion:
Prescribing ticagrelor universally increases quality-adjusted life years for ACS patients at a cost below a typically accepted threshold.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Coronary Artery Disease V: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Angina IV: Management
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations